- HiQCell Regenerative Medicine Clinic to open at prestigious Camden Medical Centre in Singapore;
- Clinic to be led by Medical Director, Dr Patrick Goh, a leading sports and exercise medical specialist;
- First treatments expected to commence in late 2014;
- Announcement signals the impending launch of Regeneus' first offshore treatment centre and a major milestone for the Company;
Regenerative medicine company, Regeneus Ltd (ASX: RGS), today announced plans to open the HiQCell Regenerative Medicine Clinic in Singapore, and the appointment of leading specialist sports physician, Dr Patrick Goh, as Medical Director.
Through the clinic, Dr Goh will provide patients in Singapore with access to Regeneus’ HiQCell, an innovative cell therapy for the treatment of osteoarthritis, with first treatments expected to commence in late 2014. As well as assuming the role of Medical Director at the HiQCell Regenerative Medicine Clinic, Dr Goh will become the initial treating medical practitioner for the HiQCell procedure.
Dr Goh is a leading sports medicine specialist who was chief medical officer for Team Singapore during the 2000 and 2004 Olympic Games. He holds a number of positions within Singapore’s Ministry of Health, the Singapore Armed Forces and Defence Science Organisation (DSO) and the National Anti-Doping Advisory Board.
Dr Goh said, “HiQCell provides a viable treatment option for mid-stage, age or impact related >osteoarthritis patients who might otherwise face ongoing debilitating pain, loss of function, inability to play sport and reduced quality of life. I am very pleased to be able to offer this treatment to my patients.”
The HiQCell Regenerative Medicine Clinic will be located at the prestigious Camden Medical Centre in Singapore’s premier medical services district on Orchard Road where a new state of the art cell-processing laboratory has been established.
Singapore provides a natural first overseas market for HiQCell as it is recognised as a leading edge medical services hub for both local and international patient treatments.
Regeneus Commercial Development Director for Human Health, Steven Barbera, said, “We are delighted to be partnering with Dr Goh at what will be a first class medical facility within Camden Medical Centre, to deliver high quality outcomes for patients.”
Regeneus CEO, Professor Graham Vesey said, “This is a very exciting announcement for Regeneus as it reports against a major milestone and highlights the first location for treatment of HiQCell outside of Australia. It makes good sense for Regeneus from a business perspective to select Singapore as the first international location for the delivery of our HiQCell treatment, as the regulatory environment is similar to what we’re used to in Australia and the standard of care is very high.”
The HiQCell treatment involves harvesting a small amount of a patient’s own stem cells from their adipose (fat) tissue and after separating and concentrating the regenerative cells these are reinjected into an osteoarthritic-affected joint such as knees, hips and ankles. The HiQCell treatment, which aims to reduce inflammation and repair damaged tissue is carried out under the supervision of the treating medical practitioner. HiQCell has been used to treat more than 500 patients and over 1,000 arthritic joints. The cell therapy procedure is supported by safety data from a randomised controlled clinical trial and long-term safety and efficacy data is tracked through Australia’s first Joint Registry for stem cell therapy.
For more information on HiQCell please call 1300 573 669 or go to the HiQCell website